SLNSW-Ivosidenib in IDH1-mutant, chemotherapy-refractor...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Full title: Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Author/creator: Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Fan, Bin, Wu, Bin, Chamberlain, Christina X, Jiang, Liewen, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Zhu, Andrew X.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    Share

    Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Full title

    Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Author / Creator

    Abou-Alfa, Ghassan K ; Macarulla, Teresa ; Javle, Milind M ; Kelley, Robin K ; Lubner, Sam J ; Adeva, Jorge ; Cleary, James M ; Catenacci, Daniel V ; Borad, Mitesh J ; Bridgewater, John ; Harris, William P ; Murphy, Adrian G ; Oh, Do-Youn ; Whisenant, Jonathan ; Lowery, Maeve A ; Goyal, Lipika ; Shroff, Rachna T ; El-Khoueiry, Anthony B ; Fan, Bin ; Wu, Bin ; Chamberlain, Christina X ; Jiang, Liewen ; Gliser, Camelia ; Pandya, Shuchi S ; Valle, Juan W ; Zhu, Andrew X

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2020, Vol.21 (6), p.796-807

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Ablation Adult Aged Aged, 80 and over Analysis Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Ascites Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - enzymology Bile Duct Neoplasms - genetics Bile Duct Neoplasms - pathology Cancer Cancer therapies Chemotherapy Cholangiocarcinoma Cholangiocarcinoma - drug therapy Cholangiocarcinoma - enzymology Cholangiocarcinoma - genetics Cholangiocarcinoma - pathology Clinical trials Consent Dehydrogenases Disease Progression Double-Blind Method Drug dosages Drug Resistance, Neoplasm Drug withdrawal Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Europe FDA approval Female Glycine - administration & dosage Glycine - adverse effects Glycine - analogs & derivatives Humans Isocitrate dehydrogenase Isocitrate Dehydrogenase - antagonists & inhibitors Isocitrate Dehydrogenase - genetics Isocitrate Dehydrogenase - metabolism Leukemia Male Medical laboratories Medical prognosis Metastasis Middle Aged Mutants Mutation Oncology Patients Progression-Free Survival Pyridines - administration & dosage Pyridines - adverse effects Quality of life Radiation therapy Regulatory approval Republic of Korea Solid tumors Survival Time Factors United States

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523268

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections